Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1), commonly known as Hematopoietic progenitor kinase 1 (HPK1), is a serine/threonine kinase predominantly expressed in hematopoietic cells, including T cells, B cells, and dendritic cells. It acts as a critical negative regulator of T-cell receptor (TCR) signaling by phosphorylating the adaptor protein SLP-76, which leads to its ubiquitination and degradation, thereby dampening T-cell activation, proliferation, and cytokine production. In the tumor microenvironment, HPK1 is chronically activated, contributing to T-cell exhaustion and allowing tumors to evade immune surveillance. Consequently, HPK1 has emerged as a highly attractive therapeutic target in immuno-oncology. Pharmacological inhibition or degradation of HPK1 using small molecules or PROTACs enhances anti-tumor immune responses, particularly when combined with immune checkpoint inhibitors like PD-1/PD-L1 antibodies. However, drug development faces challenges such as achieving selectivity over other MAP4K family members to avoid off-target toxicities, managing potential immune-related adverse events from systemic immune activation, and addressing the scaffolding functions of the protein.
Inhibition of kinase activity to prevent phosphorylation of SLP-76 and restore T-cell activation, or targeted protein degradation (PROTAC) to eliminate both kinase and scaffolding functions.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1).